For nasopharyngeal cancers ... The key difference typically lies in duration – throat cancer symptoms generally don’t improve with time or standard treatments for common ailments.

April 25, 2025 — The FDA has approved a new drug for adults with a rare type of head and neck cancer known as non-keratinizing nasopharyngeal carcinoma (NPC) after studies showed that ...

In patients with nasopharyngeal carcinoma who received induction-concurrent (chemo)radiotherapy, persistent Epstein-Barr virus (EBV) DNA positivity or its resurgence during treatment was ...

Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma. The United States Food and Drug Administration (FDA) has approved ...